Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients

AIDS

Volumn 24, Issue 6, 2010, Pages 931-932

  Calcagno, Andrea ^a   Bonora, Stefano ^a   Bertucci, Roberto ^a   Lucchini, Anna ^a   D'Avolio, Antonio ^a   Di Perri, Giovanni ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; EMTRICITABINE; ENFUVIRTIDE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RALTEGRAVIR; RIFAMPICIN; TENOFOVIR; ZIDOVUDINE;

ADULT; BRAIN DISEASE; CASE REPORT; CEREBROSPINAL FLUID; DRUG HYPERSENSITIVITY; DRUG PENETRATION; DRUG TOLERABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LEUKOENCEPHALOPATHY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

ADULT; AIDS DEMENTIA COMPLEX; CD4 LYMPHOCYTE COUNT; CHROMATOGRAPHY, LIQUID; HIV INFECTIONS; HIV-1; HUMANS; MALE; PYRROLIDINONES; RNA, VIRAL; SPINAL PUNCTURE; YOUNG ADULT;

EID: 77949545599     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283319954     Document Type: Letter

References (8)

1. Letendre SL, Marquie-Beck J, Capparelli EV, Best B, Clifford D, Collier AC, et al., and the CHARTER Group. Validation of the CNS Penetration- Effectiveness (CPE) Score for quantifying anti-retroviral penetration into the central nervous system. Arch Neurol 2008; 65:65-70.
2. Enting RH, Hoetelmans RM, Lange JM, Burger DM, Beijnen JH, Portegies P. Antiretroviral drugs and the central nervous system. AIDS 1998; 12:1941-1955.
3. Miller DS, Bauer B, Hartz AM. Modulation of p-glycoprotein at the blood-brain barrier: opportunities to improve CNS pharma-cotherapy. Pharmacol Rev 2008; 60:196-209.
4. Cocohoba J, Dong BJ. Raltegravir: the first HIV integrase inhibitor. Clin Ther 2008; 30:1747-1765.
5. Kassahun K, McIntosh I, Cui D, Hreniuk D, Merschman S, Lasseter K, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiencyvirus1integrase enzyme. Drug Metab Dispos 2007; 35:1657-1663.
6. D'Avolio A, Baietto L, Siccardi M, Sciandra M, Simiele M, Oddone V, et al. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther Drug Monit 2008; 30:662-669.
7. D'Avolio A, Siccardi M, Sciandra M, Baietto L, Bonora S, Trentini L, Di Perri G. HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. J Chro-matogr B Analyt Technol Biomed Life Sci 2007; 859:234-240.
8. Wenning LA, Hanley WD, Brainard DM, Petry AS, Ghosh K, Jin B, et al. Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009; 53:2852-2856.